Use of Systemic Corticosteroids for Atopic Dermatitis Use of Systemic Corticosteroids for Atopic Dermatitis

Despite recommendations against the use of systemic corticosteroids for atopic dermatitis, their use remains widespread. Under what limited circumstances is it appropriate to use them?The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Related Links:

Authors: Ramachandran V, Cline A, Feldman SR, Strowd LC Abstract INTRODUCTION: Atopic dermatitis (AD) is a chronic and recurrent disease presenting with eczematous lesions and pruritus. It impacts patient and family quality of life, increases morbidity, and accounts for large health-care expenditures. Although nonpharmacologic, topical, and systemic treatments exist, management of AD remains challenging due to limited treatment options. Crisaborole is a topical small molecule inhibitor of phosphodiesterase 4 (PDE4), recently approved for the treatment of AD in the United States. Areas covered: The authors review cr...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: Available online 18 April 2019Source: Actas Dermo-Sifiliográficas (English Edition)Author(s): F.J. Navarro-Triviño, S. Arias-Santiago, Y. Gilaberte-CalzadaAbstractIn recent years, the growing interest in the role played by vitamin D in skin disease has given rise to the publication of many studies of the relationship between this vitamin and certain skin conditions. As dermatologists, we need to understand, among other aspects, how vitamin D is synthesized and the main sources in humans, as well as plasma levels and the factors that can modify them. Of particular interest are the latest disc...
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Source Type: research
Allergic contact dermatitis (ACD) is a T-cell-mediated immune response to repeated contact with allergens (e.g. nickel or poison ivy). Current treatments involve topical corticosteroids, which non-specifically and transiently suppress inflammation without addressing the underlying immune dysfunction. Here we present a novel approach to induce systemic allergen-specific tolerance by delivering both allergen and a tolerance-favoring immune modifier into the same cutaneous microenvironment. Dissolvable microneedle arrays (MNAs) simultaneously deliver hapten or protein allergens with vitamin D3 analog MC903 to induce a tolerog...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research
Itch is the most bothersome symptom of atopic dermatitis (AD). Improvement in itch is an important marker of treatment benefit in AD patients. In dupilumab (DPL) phase 3, double-blind, placebo (PBO)-controlled trials, we assessed intensity and frequency of itch using Peak Pruritus Numerical Rating Scale (PP-NRS), Scoring AD (SCORAD) itch Visual Analog Scale (VAS), and Patient-Oriented Eczema Measure (POEM) itch item, in adults with moderate-to-severe AD who received DPL 300mg every 2 weeks (q2w) or PBO monotherapy (pooled SOLO 1&2: NCT02277743, NCT02277769; 16-week [Wk]), or combined with topical corticosteroids (CHRONOS: ...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Interventional Studies, Clinical and Patient Outcomes Research Source Type: research
KPL-716 is a fully-human monoclonal antibody against oncostatin M receptor beta (OSMR β), the shared receptor subunit for IL-31 and Oncostatin M (OSM) signaling. This First-In-Human, randomized, double-blind, placebo (PBO)-controlled phase 1b study assessed safety, tolerability, target engagement and Early Signal of Efficacy of single dose KPL-716 in adult subjects with moderate to severe atopic dermatitis (AD) experiencing pruritus (Worst Itch Numeric Rating Scale [WI-NRS] ≥7 at screening). The study consisted of 2 phases: KPL-716 monotherapy period (Day -7 to Day 28), when other AD medications were prohibited, an...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Interventional Studies, Clinical and Patient Outcomes Research Source Type: research
The Th2 pathway plays a central role in the pathophysiology of atopic dermatitis (AD). Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD. An ex vivo human skin model with Th2 cytokine and T-cell stimulation was used to compare the T-cell and Th2 cytokine activation effects of crisaborole with TCSs of varying potencies (hydrocortisone cream, 1% [lowest], hydrocortisone butyrate cream, 0.1% [lower-medium], and betamethasone valerate cream, 0.1% [medium]).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Pharmacology and Drug Development Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Erica S. Tarabadkar† and Michi M. Shinohara*† Division of Dermatology, University of Washington, Seattle, WA, United States Skin directed therapies (SDTs) serve important roles in the treatment of early stage cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF), as well as managing symptoms and improving quality of life of all stages. There are now numerous options for topical therapies that demonstrate high response rates, particularly in early/limited MF. Phototherapy retains an important role in treating MF, with increasing data supporting efficacy and long-term safety of both UVB and PUVA as ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Johnson BB, Franco AI, Beck LA, Prezzano JC Abstract Atopic dermatitis (AD) is a common, chronic, relapsing-remitting inflammatory disease that can be challenging to treat. Patients with mild disease are usually managed well with good skin care practices including moisturization and appropriate bathing along with intermittent use of topical therapies such as topical corticosteroids and/or topical calcineurin inhibitors during flares. Patients with frequent flares may benefit from proactive application of topical therapies twice a week to the most troublesome areas. Patients with severe disease often presen...
Source: Clinical, Cosmetic and Investigational Dermatology - Category: Dermatology Tags: Clin Cosmet Investig Dermatol Source Type: research
In this study we used HPLC and LC/MS analysis, combined with a BATMAN-TCM platform, for detailed HPLC fingerprint analysis and network pharmacology of QP, and investigated the anti-inflammatory and antipruritic activities of QP on ACD induced by squaric acid dibutylester (SADBE) in mice. The BATMAN-TCM analysis provided information of effector molecules of the main ingredients of QP, and possible chronic dermatitis-associated molecules and cell signaling pathways by QP. In ACD mice, QP treatment suppressed the scratching behavior induced by SADBE in a dose-dependent manner and inhibited the production of Th1/2 cytokines in...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Corticosteroid Therapy | Dermatitis | Dermatology | Health | Skin | UK Health